An update on efficacy and safety considerations for the latest drugs used to treat irritable bowel syndrome

References

• Enck P, Aziz Q, Barbara G, et al. Irritable bowel syndrome. Nat Rev Dis Primers. 2016;2(1):16014.
   Google Scholar
• Van den Houte K, Carbone F, Pannemans J, et al. Prevalence and impact of self-reported irritable bowel symptoms in the general population. United European Gastroenterol J. 2019;7(2):307–315.
   Google Scholar
• Corsetti M, Whorwell P. The global impact of IBS: time to think about IBS-specific models of care? Therap Adv Gastroenterol. 2017;10(9):727–736.
   Google Scholar
• Nellesen D, Yee K, Chawla A, et al. A systematic review of the economic and humanistic burden of illness in irritable bowel syndrome and chronic constipation. J Manag Care Pharm. 2013;19(9):755–764.
   Google Scholar
• Chatila R, Merhi M, Hariri E, et al. Irritable bowel syndrome: prevalence, risk factors in an adult Lebanese population. BMC Gastroenterol. 2017;17(1):137.
   Google Scholar
• Canavan C, West J, Card T. The epidemiology of irritable bowel syndrome. Clin Epidemiol. 2014;6:71–80.
   Google Scholar
• New rome IV diagnostic criteria for IBS. Philadelphia: IrritableBowelSyndrome.net. 2016 [cited 2020 Jan 4]. Available from: https://irritablebowelsyndrome.net/clinical/new-rome-iv-diagnostic-criteria/
   Google Scholar
• Rezaie A, Nikfar S, Abdollahi M. The place of antibiotics in management of irritable bowel syndrome: a systematic review and meta-analysis. Arch Med Sci. 2010;6(1):49–55.
   Google Scholar
• Simren M, Tack J. New treatments and therapeutic targets for IBS and other functional bowel disorders. Nat Rev Gastroenterol Hepatol. 2018;15(10):589–605.
   Google Scholar
• Al Harbi S. Epidemiology of irritable bowel syndrome in Saudi Arabia. Am J Med Sci. 2018;8:7–13.
   Google Scholar
• Lucak S, Chang L, Halpert A, et al. Current and emergent pharmacologic treatments for irritable bowel syndrome with diarrhea: evidence-based treatment in practice. Therap Adv Gastroenterol. 2017;10(2):253–275.
   Google Scholar
• Vahedi H, Mousavi SA, Gholamzadeh S, et al. The effect of mesalazine and nortriptyline on patients with irritable bowel syndrome with diarrhea: a randomized clinical trail [Mesalazine, Nortriptyline, Irritable bowel syndrome, Abdominal pain]. Int J Health Stud. 2017;3(1)
   Google Scholar
• Buono JL, Mathur K, Averitt AJ, et al. Economic Burden of Irritable Bowel Syndrome with Diarrhea: retrospective Analysis of a U.S. Commercially Insured Population. J Manag Care Spec Pharm. 2017;23(4):453–460.
   Google Scholar
• Lacy BE, Moreau JC. Diarrhea-predominant irritable bowel syndrome: diagnosis, etiology, and new treatment considerations. J Am Assoc Nurse Pract. 2016;28(7):393–404.
   Google Scholar
• Brenner DM, Sayuk GS. Current US Food and Drug Administration-Approved Pharmacologic Therapies for the Treatment of Irritable Bowel Syndrome with Diarrhea. Adv Ther. 2020;37(1):83–96.
   Google Scholar
• Zhu L, Huang D, Shi L, et al. Intestinal symptoms and psychological factors jointly affect quality of life of patients with irritable bowel syndrome with diarrhea. Health Qual Life Outcomes. 2015;13:49.
   Google Scholar
• NDA 21-107 LOTRONEX (alosetron hydrochloride) Tablets. Maryland: USFDA; 2000 [cited 2020 Jan 1]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21107a_Lotronex.cfm
   Google Scholar
• Randomized, double-blind, placebo-controlled phase 2 trial of BEKINDA (Ondansetron 12 mg bimodal release tablets) for diarrhea predominant irritable bowel syndrome (IBS-D). Maryland: ClinicalTrials.gov; 2016 [cited 2020 Feb 3]. Available from: https://clinicaltrials.gov/ct2/show/results/NCT02757105
   Google Scholar
• Study of LX1031 in subjects with non-constipating irritable bowel syndrome. Maryland: ClinicalTrials.gov; 2008 [cited 2020 Jan 30]. Available from: https://clinicaltrials.gov/ct2/show/study/NCT00813098
   Google Scholar
• Brown PM, Drossman DA, Wood AJJ, et al. The tryptophan hydroxylase inhibitor LX1031 shows clinical benefit in patients with nonconstipating irritable bowel syndrome. Gastroenterology. 2011;141(2):507–516.
   Google Scholar
• Morgan B. A healthy pipeline: drugs for irritable bowel syndrome have so far been limited, but a promising stream of options could soon enter the market. Nature. 2016;533:S116–S117.
   Google Scholar
• Does Welchol (Colesevelam Hydrochloride) Improve Colonic Transit in Diarrhea-predominant Irritable Bowel Syndrome (D-IBS)? (welchol). Maryland: ClinicalTrials.gov; 2009 [cited 2020 Jan 30]. Available from: https://clinicaltrials.gov/ct2/show/study/NCT00911612
   Google Scholar
• Trial to understand efficacy of colesevelam in diarrhea predominant IBS patients with bile acid malabsorption. Maryland: ClinicalTrials.gov; 2017 [cited 2020 Jan 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT03270085
   Google Scholar
• Halland M, Saito YA. Irritable bowel syndrome: new and emerging treatments. Bmj. 2015;350:h1622.
   Google Scholar
• Ranjbar S, Seyednejad SA, Nikfar S, et al. How can we develop better antispasmodics for irritable bowel syndrome? Expert Opin Drug Discov. 2019;14(6):549–562.
   Google Scholar
• Fukudo S, Matsueda K, Haruma K, et al. Optimal dose of ramosetron in female patients with irritable bowel syndrome with diarrhea: a randomized, placebo-controlled phase II study. Neurogastroenterol Motil. 2017;29(6):e13023.
   Google Scholar
• Garsed K, Chernova J, Hastings M, et al. A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea. Gut. 2014;63(10):1617–1625.
   Google Scholar
• Cremonini F, Nicandro JP, Atkinson V, et al. Randomised clinical trial: alosetron improves quality of life and reduces restriction of daily activities in women with severe diarrhoea-predominant IBS. Aliment Pharmacol Ther. 2012;36(5):437–448.
   Google Scholar
• Olden KW, Chey WD, Shringarpure R, et al. Alosetron versus traditional pharmacotherapy in clinical practice: effects on resource use, health-related quality of life, safety and symptom improvement in women with severe diarrhea-predominant irritable bowel syndrome. Curr Med Res Opin. 2019;35(3):461–472.
   Google Scholar
• Chey WD, Shringarpure R, Nicandro JPA, et al. Tu1386 alosetron treatment reduced health care utilization and improved symptoms more effectively than traditional therapy in women with severe IBS-D. Gastroenterology. 2012;142(5):S–818.
   Google Scholar
• Product information: lotronex (alosetron hydrochloride)tablets. Maryland: USFDA; 2000 [cited 2020 Feb 6]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2000/21107lbl.pdf
   Google Scholar
• Lee KJ, Kim NY, Kwon JK, et al. Efficacy of ramosetron in the treatment of male patients with irritable bowel syndrome with diarrhea: a multicenter, randomized clinical trial, compared with mebeverine. Neurogastroenterol Motil. 2011;23(12):1098–1104.
   Google Scholar
• Fukudo S, Ida M, Akiho H, et al. Effect of ramosetron on stool consistency in male patients with irritable bowel syndrome with diarrhea. Clin Gastroenterol Hepatol. 2014;12(6):953–9 e4.
   Google Scholar
• New drugs approved in FY 2015. Tokyo: Pharmaceuticals and Medical Devices Agency; 2015 [cited 2020 Feb 6]. Available from: https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html
   Google Scholar
• Products approved in FY 2008: new drugs. Tokyo: Pharmaceuticals and Medical Devices Agency; 2008 [cited 2020 Jan 29]. Available from: https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html
   Google Scholar
• Fukudo S, Kinoshita Y, Okumura T, et al. Ramosetron reduces symptoms of irritable bowel syndrome with diarrhea and improves quality of life in women. Gastroenterology. 2016;150(2):358–66 e8.
   Google Scholar
• Oral presentations. Neurogastroenterol Motility. 2016;28(S1):5–108.
   Google Scholar
• Efficacy of ramosetron hydrochloride in male patients with diarrhea-predominant irritable bowel syndrome.Tokyo: UMIN Clinical Trials Registr; 2011 [cited 2020 Feb 11]. Available from: https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000007871
   Google Scholar
• Study on the effect of a combination therapy of H2 receptor antagonist and 5-HT3 receptor antagonist for the treatment of dyspepsia with mild irritable bowel syndrome. Tokyo: UMIN Clinical Trials Registry; 2010 [cited 2020 Feb 11]. Available from: https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000004412
   Google Scholar
• Modification of neurotransmission of brain-gut interactions. Tokyo: UMIN Clinical Trials Registry; 2018 [cited 2020 Feb 11]. Available from: https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000034432
   Google Scholar
• Plasse T, Barton G, Davidson E, et al. Su1188 - randomized, double-blind, placebo-controlled, phase 2 trial of ondansetron 12 mg bimodal release tablets for diarrhea predominant irritable bowel syndrome (IBS-D). Gastroenterology. 2018;154(6):S–498.
   Google Scholar
• Murray K, Wilkinson-Smith V, Lam C, et al. OC-090 Different effects of FODMAP (fermentable oligo-, di-, and mono-saccharides, and polyols) components on small bowel water content: an MRI study. Gut. 2012;61(Suppl2):A39.2–A39.
   Google Scholar
• Abel JL, Carson RT, Andrae DA. The impact of treatment with eluxadoline on health-related quality of life among adult patients with irritable bowel syndrome with diarrhea. Qual Life Res. 2019;28(2):369–377.
   Google Scholar
• Covington PS, Dove S, Andrae D. Su1384 A retrospective assessment of area under the pain curve in quantifying daily pain assessments in irritable bowel syndrome with diarrhea. Gastroenterology. 2015;148(4):S-493–S-494.
   Google Scholar
• Brenner DM, Dove LS, Andrae DA, et al. Radar plots: A novel modality for displaying disparate data on the efficacy of eluxadoline for the treatment of irritable bowel syndrome with diarrhea. Neurogastroenterol Motil. 2018;25:e13331.
   Google Scholar
• Chey WD, Dove LS, Andrae DA, et al. Early response predicts a sustained response to eluxadoline in patients with irritable bowel syndrome with diarrhoea in two Phase 3 studies. Aliment Pharmacol Ther. 2017;45(10):1319–1328.
   Google Scholar
• Cash BD, Lacy BE, Schoenfeld PS, et al. Safety of eluxadoline in patients with irritable bowel syndrome with diarrhea. Am J Gastroenterol. 2017;112(2):365–374.
   Google Scholar
• Brenner DM, Sayuk GS, Gutman CR, et al. Efficacy and safety of eluxadoline in patients with irritable bowel syndrome with diarrhea who report inadequate symptom control with loperamide: RELIEF phase 4 study. Am J Gastroenterol. 2019;114(9):1502–1511.
   Google Scholar
• Lacy BE, Chey WD, Cash BD, et al. Eluxadoline efficacy in IBS-D patients who report prior loperamide use. Am J Gastroenterol. 2017;112(6):924–932.
   Google Scholar
• Cash BD, Brenner DM, Elmes S, et al. 442 – safety profile of eluxadoline in patients with irritable bowel syndrome with diarrhea reporting inadequate symptom control with prior loperamide use: a phase 4 study (Relief). Gastroenterology. 2019;156(6):S-91–S-92.
   Google Scholar
• Efficacy of eluxadoline in the treatment of irritable bowel syndrome with diarrhea in patients with inadequate control of symptoms with prior loperamide use. Maryland: ClinicalTrials.gov; 2019 [cited 2020 Feb 11]. Available from: https://clinicaltrials.gov/ct2/show/results/NCT02959983
   Google Scholar
• Meeting abstracts - academy of managed care pharmacy nexus 2018. J Manag Care Spec Pharm. 2018;24(10–aSuppl):S1–S112.
   Google Scholar
• Levy-Cooperman N, McIntyre G, Bonifacio L, et al. Abuse potential and pharmacodynamic characteristics of oral and intranasal eluxadoline, a mixed mu- and kappa-opioid receptor agonist and delta-opioid receptor antagonist. J Pharmacol Exp Ther. 2016;359(3):471–481.
   Google Scholar
• Study to explore the therapeutic effect of eluxadoline in treating irritable bowel syndrome with diarrhea in children. Maryland: ClinicalTrials.gov; 2017 [cited 2020 Feb 11]. Available from: https://clinicaltrials.gov/ct2/show/NCT03339128
   Google Scholar
• A phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Evaluate the Safety and Efficacy of Eluxadoline in Pediatric Patients (Age 12 to 17 Years) with Irritable Bowel Syndrome with Diarrhea (IBS-D). Geneva: international Clinical Trials Registry Platform-WHO; 2018 [cited 2020 Feb 11]. Available from: http://apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2017%E2%80%90003770%E2%80%9014%E2%80%90DE
   Google Scholar
• 3030-401-002 ELX BAM Study. Maryland: ClinicalTrials.gov; 2018 [cited 2020 Feb 11]. Available from: https://clinicaltrials.gov/ct2/show/NCT03441581
   Google Scholar
• A comparison of three different treatment options for irritable bowel syndrome (Car-IBS). Maryland: ClinicalTrials.gov; 2016 [cited 2020 Feb 11]. Available from: https://clinicaltrials.gov/ct2/show/NCT02970591
   Google Scholar
• Viberzi (eluxadoline) tablets. Maryland: U.S. Food and Drug Administration; 2015 [cited 2020 Jan 5]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206940Orig1s000TOC.cfm
   Google Scholar
• Truberzi: eluxadoline. Amsterdam: European Medicines Agency; 2016 [cited 2020 Jan 14]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/truberzi
   Google Scholar
• Hicks GA, Kovar A, Urso DM, et al. Tu1405 the kappa-opioid receptor agonist asimadoline remains peripherally restricted at supra-therapeutic plasma exposures. Gastroenterology. 2012;142(5):S–824.
   Google Scholar
• A comparison of the effects of ORP-101 versus placebo in adult patients with irritable bowel syndrome with diarrhea (IBS-D). Maryland: ClinicalTrials.gov; 2019 [cited 2020 Feb 11]. Available from: https://clinicaltrials.gov/ct2/show/NCT04129619
   Google Scholar
• Kemppinen A, Howell C, Allgar V, et al. Randomised, double-blind, placebo controlled multi-centre study to assess the efficacy, tolerability and safety of Enterosgel(R) in the treatment of irritable bowel syndrome with diarrhoea (IBS-D) in adults. Trials. 2020;21(1):122.
   Google Scholar
• Nikolaev VG, editor. Enterosgel: a novel organosilicon enterosorbent with a wide range of medical applications. biodefence. Dordrecht: Springer Netherlands; 2011.
   Google Scholar
• Randomised, double-blind, placebo-controlled multi-centre study to assess the efficacy, tolerability and safety of Enterosgel® in the treatment of Irritable Bowel Syndrome with Diarrhoea (IBS-D) in adults (RELIEVE IBS-D). Geneva: International Clinical Trials Registry Platform-WHO; 2017 [cited 2020 Feb 5]. Available from: http://apps.who.int/trialsearch/Trial2.aspx?TrialID=ISRCTN17149988
   Google Scholar
• Tack JF, Miner PB Jr., Fischer L, et al. Randomised clinical trial: the safety and efficacy of AST-120 in non-constipating irritable bowel syndrome - a double-blind, placebo-controlled study. Aliment Pharmacol Ther. 2011;34(8):868–877.
   Google Scholar
• Olorinab in IBS-C and IBS-D (CAPTIVATE). Maryland: ClinicalTrials.gov; 2019 [cited 2020 Feb 11]. Available from: https://clinicaltrials.gov/ct2/show/NCT04043455
   Google Scholar
• HIGHLIGHTS OF PRESCRIBING INFORMATION: rifaximin. Maryland: ClinicalTrials.gov; 2017 [cited 2020 Feb 5]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021361s023lbl.pdf
   Google Scholar
• Guda NM, Reddy DN, Kumar A; Indian Society of Gastroenterology. Complications of ERCP.. Indian J Gastroenterol. 2014;33(S1):1–107.
   Google Scholar
• Fodor AA, Pimentel M, Chey WD, et al. Rifaximin is associated with modest, transient decreases in multiple taxa in the gut microbiota of patients with diarrhoea-predominant irritable bowel syndrome. Gut Microbes. 2019;10(1):22–33.
   Google Scholar
• Functional bowel disorders. Am J Gastroenterol. 2011;106(S2):S495–S516.
   Google Scholar
• Functional bowel disease. Am J Gastroenterol. 2015;110(Suppl 1):S739–66.
   Google Scholar
• Schoenfeld P, Pimentel M, Chang L, et al. Safety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation: a pooled analysis of randomised, double-blind, placebo-controlled trials. Aliment Pharmacol Ther. 2014;39(10):1161–1168.
   Google Scholar
• Lembo AJ, Rao SS, Rezaie A, et al. Su1194 - efficacy of rifaximin in patients with diarrhea-predominant irritable bowel syndrome (IBS-D) and prior use of IBS medications. Gastroenterology. 2018;154(6):S–499.
   Google Scholar
• Chey WD, Chang L, Lembo A, et al. 313 effects of rifaximin on urgency, bloating, and abdominal pain in patients with IBS-D: a randomized, controlled, repeat treatment study. Gastroenterology. 2015;148(4):S–69.
   Google Scholar
• Cash BD, Lembo A, Aggarwal K, et al. Mo1291 improvements in IBS-related quality of life in a randomized, controlled repeat treatment trial (TARGET 3) of rifaximin for IBS-D. Gastroenterology. 2015;148(4):S–663.
   Google Scholar
• Functional bowel disease. Am J Gastroenterol. 2016;111(S1):S236–S260.
   Google Scholar
• Indian Society of Gastroenterology. Indian J Gastroenterol. 2013.
   Google Scholar
• Tuteja AK, Talley NJ, Stoddard GJ, et al. Double-blind placebo-controlled study of rifaximin and lactulose hydrogen breath test in gulf war veterans with irritable bowel syndrome. Dig Dis Sci. 2019;64(3):838–845.
   Google Scholar
• Bae S, Lee KJ, Kim YS, et al. Determination of rifaximin treatment period according to lactulose breath test values in nonconstipated irritable bowel syndrome subjects. J Korean Med Sci. 2015;30(6):757–762.
   Google Scholar
• Pimentel M, Chang C, Chua KS, et al. Antibiotic treatment of constipation-predominant irritable bowel syndrome. Dig Dis Sci. 2014;59(6):1278–1285.
   Google Scholar
• Abstracts-APASL 2013. Hepatol Int. 2013;7(Suppl 1):1–754.
   Google Scholar
• Effects of continuous treatment with rifaximin and probiotics on the gut microbiota of patients with IBS-D. Maryland: ClinicalTrials.gov; 2019 [cited 2020 Feb 14]. Available from: https://clinicaltrials.gov/ct2/show/NCT04074421
   Google Scholar
• Schoenfeld PS. Advances in IBS 2016: A review of current and emerging data. Gastroenterol Hepatol. 2016;12(8 Suppl 3):1–11.
   Google Scholar
• Niewinna K, Zielinska A, Fichna J. Recent advances in the pharmacological management of constipation predominant irritable bowel syndrome. Expert Opin Pharmacother. 2020;21(1):73–84.
   Google Scholar
• Chapman RW, Stanghellini V, Geraint M, et al. Randomized clinical trial: macrogol/PEG 3350 plus electrolytes for treatment of patients with constipation associated with irritable bowel syndrome. Am J Gastroenterol. 2013;108(9):1508–1515.
   Google Scholar
• Awad RA, Camacho S. A randomized, double-blind, placebo-controlled trial of polyethylene glycol effects on fasting and postprandial rectal sensitivity and symptoms in hypersensitive constipation-predominant irritable bowel syndrome. Colorectal Dis. 2010;12(11):1131–1138.
   Google Scholar
• Highlights of prescribing information: tegaserod. Maryland: U.S. Food and Drug Administration; 2019 [cited 2020 Feb 6]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021200Orig1s015lbl.pdf
   Google Scholar
• Zelnorm (tegaserod). Amsterdam: European Medicines Agency; 2009 [cited 2020 Feb 5]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/zelnorm
   Google Scholar
• Howden CW, Gerlach R, Byers A, et al. Mo1546 – time to onset of tegaserod effect on Ibs-C patients’ global assessment of symptom relief. Gastroenterology. 2019;156(6):S–775.
   Google Scholar
• Questions and answers on recommendation for refusal of marketing application for Zelnorm. Amsterdam: European Medicines Agency; 2006 [cited 2020 Feb 5]. Available from: https://www.ema.europa.eu/en/documents/smop-initial/questions-answers-recommendation-refusal-marketing-authorisation-zelnorm_en.pdf
   Google Scholar
• Constella. Amsterdam: European Medicines Agency; 2012 [cited 2020 Feb 5]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/constella
   Google Scholar
• New drugs approved in FY 2016. Tokyo: Pharmaceuticals and Medical Devices Agency; 2016 [cited 2020 Feb 22]. Available from: https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html
   Google Scholar
• CONSTELLA linaclotide 290 microgram hard capsule bottle. Symonston: Therapeutic Goods Administration; 2019 [cited 2020 Feb 23]. Available from: http://search.tga.gov.au/s/search.html?collection=tga-artg&profile=record&meta_i=297704
   Google Scholar
• Highlights of prescribing information: plecanatide. Maryland: U.S. Food and Drug Administration; 2018 [cited 2020 Jan 5]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208745s001lbl.pdf
   Google Scholar
• Rao S, Lembo AJ, Shiff SJ, et al. A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation. Am J Gastroenterol. 2012;107(11):1714–1724.
   Google Scholar
• Pearl DS, Higginson A, Quine A. PTU-151 Small bowel ultrasound: diagnostic yield in established small bowel Crohn’s disease. Gut. 2012;61(Suppl2):A247.1-A247.
   Google Scholar
• Buono JL, Tourkodimitris S, Sarocco P, et al. Impact of linaclotide on work productivity and daily activity impairment among adults with irritable bowel syndrome with constipation: results from a 26-week phase 3 trial. Value Health. 2014;17(3):A38–A39.
   Google Scholar
• Chey WD, Lembo AJ, Lavins BJ, et al. Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety. Am J Gastroenterol. 2012;107(11):1702–1712.
   Google Scholar
• Currie M, Shiff S, Hao X, et al. PWE-167 effect of linaclotide on Ibs-qol sexual subscale scores in patients with irritable bowel syndrome with constipation: results from 2 phase 3 trials. Gut. 2014;63:A198.
   Google Scholar
• Chey W, Shiff S, Schneier H, et al. Two Years on Linaclotide: tolerability and Treatment Satisfaction in IBS-C Patients With and Without Diarrhea: presidential Poster: 1791. Am J Gastroenterol. 2014;109:S530.
   Google Scholar
• Highlights of prescribing information: linaclotide. Maryland: U.S. Food and Drug Administration; 2017 [cited 2020 Jan 13]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/202811s010lbl.pdf
   Google Scholar
• Chey WD, Chamberlin P, Bochenek W, et al. Targeted delivery of linaclotide to specific areas of the intestine affects clinical efficacy in patients with irritable bowel syndrome with constipation (IBS-C). Gastroenterology. 2017;152(5):S1314–S1315.
   Google Scholar
• Fukudo S, Nakajima A, Fujiyama Y, et al. Determining an optimal dose of linaclotide for use in Japanese patients with irritable bowel syndrome with constipation: A phase II randomized, double-blind, placebo-controlled study. Neurogastroenterol Motil. 2018;30(5):e13275.
   Google Scholar
• Brenner DM, Sayuk GS. Tu1645 - efficacy of plecanatide for the treatment of irritable bowel syndrome with constipation: use of radar plots to express aggregated multivariate results from two phase III placebo-controlled trials. Gastroenterology. 2018;154(6):S–980.
   Google Scholar
• Chang C, Chong K, Magnus L, et al. Mo1541 – plecanatide improved patient global rating of IBS symptoms and quality of life in adult patients with Ibs-C. Gastroenterology. 2019;156(6):S–773.
   Google Scholar
• Brenner DM, Fogel R, Dorn SD, et al. Efficacy, safety, and tolerability of plecanatide in patients with irritable bowel syndrome with constipation: results of two phase 3 randomized clinical trials. Am J Gastroenterol. 2018;113(5):735–745.
   Google Scholar
• The plecanatide irritable bowel syndrome with constipation study (IBS-C). Maryland: ClinicalTrials.gov; 2015 [cited 2020 Feb 13]. Available from: https://clinicaltrials.gov/ct2/show/results/NCT02387359
   Google Scholar
• Second plecanatide study in irritable bowel syndrome with constipation (IBS-C). Maryland: ClinicalTrials.gov; 2015 [cited 2020 Feb 13]. Available from: https://clinicaltrials.gov/ct2/show/results/NCT02493452
   Google Scholar
• Efficacy and safety of plecanatide in children 6 to <18 years of age with irritable bowel syndrome with constipation (IBS-C). Maryland: ClinicalTrials.gov; 2018 [cited 2020 Feb 13]. Available from: https://clinicaltrials.gov/ct2/show/NCT03596905
   Google Scholar
• A safety and efficacy study of a range of linaclotide doses administered orally to children ages 7–17 years, with irritable bowel syndrome with constipation (LIN-MD-63). Maryland: ClinicalTrials.gov; 2015 [cited 2020 Feb 13]. Available from: https://clinicaltrials.gov/ct2/show/NCT02559817
   Google Scholar
• A study of the effect of linaclotide on abdominal girth in participants with IBS-C. Maryland: ClinicalTrials.gov; 2016 [cited 2020 Feb 13]. Available from: https://clinicaltrials.gov/ct2/show/NCT02837783
   Google Scholar
• A phase 4, single-centre, randomised, double-blind, placebo-controlled, parallel-group, fixed-dose study of the effect of linaclotide on abdominal girth in participants with irritable bowel syndrome with constipation. Amsterdam: EU Clinical Trials Register; 2016 [cited 2020 Feb 13]. Available from: https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-000818-29/GB#G
   Google Scholar
• Highlights of prescribing information: lubiprostone. Maryland: U.S. Food and Drug Administration; 2012 [cited 2020 Jan 1]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021908s010lbl.pdf
   Google Scholar
• Chang L, Chey WD, Drossman D, et al. Effects of baseline abdominal pain and bloating on response to lubiprostone in patients with irritable bowel syndrome with constipation. Aliment Pharmacol Ther. 2016;44(10):1114–1122.
   Google Scholar
• Chey WD, Drossman DA, Johanson JF, et al. Safety and patient outcomes with lubiprostone for up to 52 weeks in patients with irritable bowel syndrome with constipation. Aliment Pharmacol Ther. 2012;35(5):587–599.
   Google Scholar
• Drossman DA, Chey WD, Johanson JF, et al. Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome–results of two randomized, placebo-controlled studies. Aliment Pharmacol Ther. 2009;29(3):329–341.
   Google Scholar
• Evaluation of the efficacy and safety of lubiprostone in adults with mixed or unsubtyped irritable bowel syndrome. Maryland: ClinicalTrials.gov; 2015 [cited 2020 Feb 13]. Available from: https://clinicaltrials.gov/ct2/show/results/NCT02544152
   Google Scholar
• Kearbey J, McGraw T, O’Mullane J, et al. Performance differences between Zegerid® and PrilosecTM dosage forms: a comparative bioavailability study. Am J Gastroenterol. 2013;108:S561.
   Google Scholar
• Whitehead WE, Palsson OS, Gangarosa L, et al. Lubiprostone does not influence visceral pain thresholds in patients with irritable bowel syndrome. Neurogastroenterol Motil. 2011;23(10):944–e400.
   Google Scholar
• Joswick TR, Woldegeorgis F, Ueno R. Su1198 patient response to lubiprostone for the treatment of moderate to severe irritable bowel syndrome with constipation (IBS-C). Gastroenterology. 2012;142(5):S-449.
   Google Scholar
• Fukudo S, Hongo M, Kaneko H, et al. Efficacy and safety of oral lubiprostone in constipated patients with or without irritable bowel syndrome: a randomized, placebo-controlled and dose-finding study. Neurogastroenterol Motil. 2011;23(6):544–e205.
   Google Scholar
• Comparison of drug efficacy between linaclotide and lubiprostone in constipation-predominant irritable bowel syndrome patients. Geneva: International Clinical Trials Registry Platform-WHO; 2017 [cited 2020 Feb 13]. Available from: http://apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN%E2%80%90UMIN000028709
   Google Scholar
• Highlights of prescribing information: tenapanor. Maryland: U.S. Food and Drug Administration; 2019 [cited 2020 Feb 6]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211801s000lbl.pdf
   Google Scholar
• Chey WD, Lembo AJ, Yan A, et al. 885 - efficacy and safety of tenapanor in patients with constipation predominant irritable bowel syndrome: a 6-month, double-blind, placebo-controlled phase 3 trial (T3MPO-2). Gastroenterology. 2018;154(6):S–1362.
   Google Scholar
• Chey WD, Lembo AJ, Rosenbaum DP. Efficacy of tenapanor in treating patients with irritable bowel syndrome with constipation: a 12-week, placebo-controlled phase 3 trial (T3MPO-1). Am J Gastroenterol. 2020;115(2):281–293.
   Google Scholar
• Chey WD, Lembo A, Phillips JA, et al. 1020 efficacy and safety of tenapanor in patients with constipation predominant irritable bowel syndrome: A 12-week, double-blind, placebo-controlled, randomized phase 2B trial. Gastroenterology. 2015;148(4):S-191–S-192.
   Google Scholar
• Chey WD, Lembo AJ, Rosenbaum DP. Tenapanor treatment of patients with constipation-predominant irritable bowel syndrome: a phase 2, randomized, placebo-controlled efficacy and safety trial. Am J Gastroenterol. 2017;112(5):763–774.
   Google Scholar
• Effects of ROSE-010 on GI transit in constipation predominant irritable bowel syndrome (C-IBS) patients.Maryland: ClinicalTrials.gov; 2010 [cited 2020 Feb 5]. Available from: https://clinicaltrials.gov/ct2/show/study/NCT01056107
   Google Scholar
• Camilleri M, Vazquez-Roque M, Iturrino J, et al. Effect of a glucagon-like peptide 1 analog, ROSE-010, on GI motor functions in female patients with constipation-predominant irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol. 2012;303(1):G120–8.
   Google Scholar
• UEG week 2016 poster presentations. United European Gastroenterol J. 2016;4(5_suppl):A157–A720.
   Google Scholar
• Fabisiak A, Wlodarczyk J, Fabisiak N, et al. Targeting histamine receptors in irritable bowel syndrome: a critical appraisal. J Neurogastroenterol Motil. 2017;23(3):341–348.
   Google Scholar
• van Wanrooij S, Wouters MM, Van Oudenhove L, et al. 901 effect of the H1-receptor antagonist ebastin on visceral perception and clinical symptoms in IBS. Gastroenterology. 2013;144(5):S–160.
   Google Scholar
• Histamine 1 receptor antagonist ebastine as novel treatment in IBS. Amsterdam: EU Clinical Trials Register 2013 [cited 2020 Feb 6]. Available from: https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-001199-39/BE
   Google Scholar
• Odunsi–Shiyanbade ST, Camilleri M, McKinzie S, et al. Effects of chenodeoxycholate and a bile acid sequestrant, colesevelam, on intestinal transit and bowel function. Clin Gastroenterol Hepatol. 2010;8(2):159–165.
   Google Scholar
• A study of the effect of SYN-010 on subjects with IBS-C. Maryland: ClinicalTrials.gov; 2015 [cited 2020 Feb 5]. Available from: https://clinicaltrials.gov/ct2/show/study/NCT02495623
   Google Scholar
• A single-dose, open-label, study to evaluate the sustainability of the effects of SYN-010 in patients with IBS-C. Maryland: ClinicalTrials.gov; 2015 [cited 2020 Feb 5]. Available from: https://clinicaltrials.gov/ct2/show/results/NCT02493036
   Google Scholar
• Irritable bowel syndrome (IBS) treatment with H1-receptor antagonists. Maryland: ClinicalTrials.gov; 2010 [cited 2020 Feb 5]. Available from: https://clinicaltrials.gov/ct2/show/NCT01144832
   Google Scholar
• Nakajima A, Seki M, Taniguchi S. Determining an optimal clinical dose of elobixibat, a novel inhibitor of the ileal bile acid transporter, in Japanese patients with chronic constipation: a phase II, multicenter, double-blind, placebo-controlled randomized clinical trial. J Gastroenterol. 2018;53(4):525–534.
   Google Scholar
• Rao AS, Wong BS, Camilleri M, et al. Chenodeoxycholate in females with irritable bowel syndrome-constipation: a pharmacodynamic and pharmacogenetic analysis. Gastroenterology. 2010;139(5):1549–1558.
   Google Scholar
• Oral abstracts. J Gastroenterol Hepatol. 2011;26(s5):1–15.
   Google Scholar
• Clave P, Acalovschi M, Triantafillidis JK, et al. Randomised clinical trial: otilonium bromide improves frequency of abdominal pain, severity of distention and time to relapse in patients with irritable bowel syndrome. Aliment Pharmacol Ther. 2011;34(4):432–442.
   Google Scholar
• Ibodutant for relief of irritable bowel syndrome (IRIS). Maryland: ClinicalTrials.gov; 2008 [cited 2020 Jan 30]. Available from: https://clinicaltrials.gov/ct2/show/record/NCT00761007?view=record
   Google Scholar
• Ibodutant for relief of irritable bowel syndrome with diarrhoea (IBS-D)(IRIS-2). Maryland: ClinicalTrials.gov; 2011 [cited 2020 Jan 30]. Available from: https://clinicaltrials.gov/ct2/show/study/NCT01303224
   Google Scholar
• Menarini Group. Ibodutant for relief of irritable bowel syndrome with diarrhoea (IBS-D)(IRIS-2). Maryland: ClinicalTrials.gov; [cited 2020 Jan 4]. Available from: https://clinicaltrials.gov/ct2/show/NCT01303224
   Google Scholar
• Tack JF, Madami A, Scartoni S, et al. Mo1056 weekly assessment of satisfactory relief vs. quantitative daily assessment of signs and symptoms in IBS: do they provide comparable data? The IRIS-2 study experience with ibodutant in IBS-D. Gastroenterology. 2013;144(5):S-565–S-566.
   Google Scholar
• 12-week efficacy and safety study of ibodutant in women with irritable bowel syndrome with diarrhea (IBS-D)(IRIS-3). Maryland: ClinicalTrials.gov; 2016 [cited 2020 Jan 30]. Available from: https://clinicaltrials.gov/ct2/show/study/NCT02107196
   Google Scholar
• 52-week efficacy and safety study of ibodutant in women with irritable bowel syndrome with diarrhea (IBS-D)(IRIS-4). Maryland: ClinicalTrials.gov; 2017 [cited 2020 Jan 30]. Available from: https://clinicaltrials.gov/ct2/show/study/NCT02120027
   Google Scholar
• Shin SY, Cha BK, Kim W-S, et al. The effect of phloroglucinol in patients with diarrhea-predominant irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial. J Neurogastroenterol Motil. 2020;26(1):117–127.
   Google Scholar
• Riva A, Giacomelli L, Togni S, et al. Oral administration of a lecithin-based delivery form of boswellic acids (Casperome®) for the prevention of symptoms of irritable bowel syndrome: a randomized clinical study. Minerva Gastroenterol Dietol. 2019;65(1):30–35.
   Google Scholar
• Cash BD, Epstein MS, Shah SM. A novel delivery system of peppermint oil is an effective therapy for irritable bowel syndrome symptoms. Dig Dis Sci. 2016;61(2):560–571.
   Google Scholar
• Menthae piperitae aetheroleum.Amsterdam: european Medicines Agency; 2019 [cited 2020 Feb 23]. Available from: https://www.ema.europa.eu/en/medicines/herbal/menthae-piperitae-aetheroleum
   Google Scholar
• Merat S, Khalili S, Mostajabi P, et al. The effect of enteric-coated, delayed-release peppermint oil on irritable bowel syndrome. Dig Dis Sci. 2010;55(5):1385–1390.
   Google Scholar
• Weerts Z, Masclee AAM, Witteman BJM, et al. Efficacy and safety of peppermint oil in a randomized, double-blind trial of patients with irritable bowel syndrome. Gastroenterology. 2020;158(1):123–136.
   Google Scholar
• PRODUCT INFORMATION: COLOFAC. Symonston: therapeutic Goods Administration; 2017 [cited 2020 Feb 22]. Available from: https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/PICMI?OpenForm&t=&q=mebeverine
   Google Scholar
• Dumitrascu DL, Chira A, Bataga S, et al. The use of mebeverine in irritable bowel syndrome. A Position paper of the Romanian Society of Neurogastroenterology based on evidence. J Gastrointestin Liver Dis. 2014;23(4):431–435.
   Google Scholar
• Darvish-Damavandi M, Nikfar S, Abdollahi M. A systematic review of efficacy and tolerability of mebeverine in irritable bowel syndrome. World J Gastroenterol. 2010;16(5):547–553.
   Google Scholar
• Chakraborty DS, Hazra A, Sil A, et al. Will controlled release mebeverine be able to surpass placebo in treatment of diarrhoea predominant irritable bowel syndrome? J Family Med Prim Care. 2019;8(10):3173–3178.
   Google Scholar
• Rai RR, Dwivedi M, Kumar N. Efficacy and safety of drotaverine hydrochloride in irritable bowel syndrome: a randomized double-blind placebo-controlled study. Saudi J Gastroenterol. 2014;20:378–382.
   Google Scholar
• Saito Y, Almazar A, Tilkes K, et al. Randomised clinical trial: pregabalin vs placebo for irritable bowel syndrome. Aliment Pharmacol Ther. 2019;49:389–397.
   Google Scholar
• Zheng L, Lai Y, Lu W, et al. Pinaverium reduces symptoms of irritable bowel syndrome in a multi-center, randomized controlled trial. Clin Gastroenterol Hepatol. 2015;13:1285–1292.
   Google Scholar
• Kulak-Bejda A, Bejda G, Waszkiewicz N. Antidepressants for irritable bowel syndrome-A systematic review. Pharmacol Rep. 2017;69(6):1366–1379.
   Google Scholar
• Drossman D, Tack J, Ford A, et al. Neuromodulators for functional GI disorders (Disorders of gut-brain interaction): A Rome Foundation Working Team Report. Gastroenterology. 2017;154:1140–1171.
   Google Scholar
• Black C, Yuan Y, Selinger C, et al. Efficacy of soluble fibre, antispasmodic drugs, and gut–brain neuromodulators in irritable bowel syndrome: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol. 2019;5:117–131.
   Google Scholar
• Bundeff AW, Woodis CB. Selective serotonin reuptake inhibitors for the treatment of irritable bowel syndrome. Ann Pharmacother. 2014;48(6):777–784.
   Google Scholar
• Wilkins T, Agabin E, Blake L. Effectiveness of selective serotonin reuptake inhibitors for irritable bowel syndrome. Am Fam Physician. 2015;92(9):Online.
   Google Scholar
• Xie C, Tang Y, Wang Y, et al. Efficacy and safety of antidepressants for the treatment of irritable bowel syndrome: a meta-analysis. PLoS One. 2015;10(8):e0127815.
   Google Scholar
• Rahimi R, Nikfar S, Abdollahi M. Selective serotonin reuptake inhibitors for the management of irritable bowel syndrome: a meta-analysis of randomized controlled trials. Arch Med Sci. 2008;4(1):71–76.
   Google Scholar
• Masand P, Pae C-U, Krulewicz S, et al. A double-blind, randomized, placebo-controlled trial of paroxetine controlled-release in irritable bowel syndrome. Psychosomatics. 2009;50:78–86.
   Google Scholar
• Ladabaum U, Sharabidze A, Levin T, et al. Citalopram is not-effective therapy for non depressed patiants with irritabl bowel syndrome. Clin Gastroenterol Hepatol. 2010;81(1):42.
   Google Scholar
• Rahimi R, Nikfar S, Rezaie A, et al. Efficacy of tricyclic antidepressants in irritable bowel syndrome: a meta-analysis. World J Gastroenterol. 2009;15(13):1548–1553.
   Google Scholar
• Abdul-Baki H, El Hajj I, Zahabi L, et al. A randomized controlled trial of imipramine in patients with irritable bowel syndrome. World J Gastroenterol. 2009;15:3636–3642.
   Google Scholar
• Ghadir MR, Habibinejad H, Heidari A, et al. Doxepin is more effective than nortriptyline and placebo for the treatment of diarrhea-predominant irritable bowel syndrome: a randomized triple-blind placebo-controlled trial. Tehran Univ Med J. 2011;69:352–358.
   Google Scholar
• Voss U, Lewerenz A, Nieber K. Treatment of irritable bowel syndrome: sex and gender specific aspects. Handb Exp Pharmacol. 2012;214:473–497.
   Google Scholar
• Kaplan A, Franzen M, Nickell P, et al. An open label trial of duloxetine in patients with irritable bowel syndrome and comorbid generalized anxiety disorder. Int J Psychiatry Clin Pract. 2013;18:11–15.
   Google Scholar
• Saha L. Irritable bowel syndrome: pathogenesis, diagnosis, treatment, and evidence-based medicine. World J Gastroenterol. 2014;20(22):6759–6773.
   Google Scholar
• Hosseini A, Nikfar S, Abdollahi M. Are probiotics effective in management of irritable bowel syndrome? Arch Med Sci. 2012;8(3):403–405.
   Google Scholar
• Niu HL, Xiao JY. The efficacy and safety of probiotics in patients with irritable bowel syndrome: evidence based on 35 randomized controlled trials. Int J Surg. 2020;75:116–127.
   Google Scholar
• Didari T, Mozaffari S, Nikfar S, et al. Effectiveness of probiotics in irritable bowel syndrome: updated systematic review with meta-analysis. World J Gastroenterol. 2015;21(10):3072–3084.
   Google Scholar
• Sun JR, Kong CF, Qu XK, et al. Efficacy and safety of probiotics in irritable bowel syndrome: A systematic review and meta-analysis. Saudi J Gastroenterol. 2020;26:66–77.
   Google Scholar
• Sotoudegan F, Daniali M, Hassani S, et al. Reappraisal of probiotics’ safety in human. Food Chem Toxicol. 2019;129:22–29.
   Google Scholar
• ARTG: probiotics.Symonston: therapeutic Goods Administration; 2020 [cited 2020 Feb 23]. Available from: https://tga-search.clients.funnelback.com/s/search.html?query=probiotics+FOR+IBS&collection=tga-artg
   Google Scholar
• Rahimi R, Abdollahi M. Herbal medicines for the management of irritable bowel syndrome: a comprehensive review. World J Gastroenterol. 2012;18(7):589–600.
   Google Scholar
• Abstracts. J Gastroenterol Hepatol. 2016;31:7–441.
   Google Scholar
• Chen M, Tang TC, Wang Y, et al. Randomised clinical trial: tong-Xie-Yao-Fang granules versus placebo for patients with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2018;48(2):160–168.
   Google Scholar
• Tang XD, Zhang SS, Hou XH, et al. Post-marketing re-evaluation of tongxiening granules in treatment of diarrhea-predominant irritable bowel syndrome: a multi-center, randomized, double-blind, double-dummy and positive control trial. Chin J Integr Med. 2019;25(12):887–894.
   Google Scholar
• Barbara G, Fukudo S, Drummond L, et al. Tu1644 - green kiwifruit compared to psyllium for the relief of constipation and improving digestive comfort in patients with functional constipation and constipation predominant irritable bowel syndrome — analysis of three international trial centres. Gastroenterology. 2018;154(6):S-979–S-980.
   Google Scholar
• Malfertheiner P. STW 5 (Iberogast) therapy in gastrointestinal functional disorders. Dig Dis. 2017;35(Suppl 1):25–29.
   Google Scholar
• Hutchings HA, Wareham K, Baxter JN, et al. A randomised, cross-over, placebo-controlled study of aloe vera in patients with irritable bowel syndrome: effects on patient quality of life. ISRN Gastroenterol. 2011;2011:206103.
   Google Scholar
• Roe B, Kensicki E, Mohney R, et al. Metabolomic profile of hepatitis C virus-infected hepatocytes. PLoS One. 2011;6(8):e23641.
   Google Scholar
• Black CJ, Burr NE, Camilleri M, et al. Efficacy of pharmacological therapies in patients with IBS with diarrhoea or mixed stool pattern: systematic review and network meta-analysis. Gut. 2020;69(1):74–82.
   Google Scholar
• Li YH, Gupta PJ, Sawant R, et al. A cost-effectiveness comparison of alosetron, eluxadoline, and rifaximin in the treatment of irritable bowel syndrome with diarrhea. Pharm Pharmacol Int J 2016;4(6):450-458.
   Google Scholar
• Ford AC, Harris LA, Lacy BE, et al. Systematic review with meta-analysis: the efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome. Aliment Pharmacol Ther. 2018;48(10):1044–1060.
   Google Scholar
• Huang H, Taylor DC, Carson RT, et al. Economic evaluation of linaclotide for the treatment of adult patients with irritable bowel syndrome with constipation in the United States. J Med Econ. 2015;18(4):283–294.
   Google Scholar
• CDR Pharmacoeconomic Review Report for Constella - Cadth. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2015 [cited 2020 Feb 24]. Available from: https://www.cadth.ca/sites/default/files/cdr/pharmacoeconomic/SR0409_Constella_PE_Report.pdf
   Google Scholar
• Black CJ, Burr NE, Quigley EMM, et al. Efficacy of secretagogues in patients with irritable bowel syndrome with constipation: systematic review and network meta-analysis. Gastroenterology. 2018;155(6):1753–1763.
   Google Scholar
• Hill P, Muir J, Gibson P. Controversies and recent developments of the low-FODMAP diet. Gastroenterol Hepatol. 2017;13:36–45.
   Google Scholar
• Halmos E, Gibson P. Controversies and reality of the FODMAP diet for patients with irritable bowel syndrome. J Gastroenterol Hepatol. 2019;34:1134–1142.
   Google Scholar
• Molina-Infante J, Serra J, Fernández-Bañares F, et al. The low-FODMAP diet for irritable bowel syndrome: lights and shadows. Gastroenterol Hepatol. 2015;39:55–65.
   Google Scholar